Novanta’s Perfect Storm Is a Factory, Not a Demand Problem
Record margins, a sold-out spindle franchise and a $543M backlog ran into a self-inflicted Q4 gross-margin reset—and a stock already 27% below its August peak.
NOVT · Earnings Call · 2026-11-10
The beat that couldn’t lift the stock
Novanta’s third quarter was, on the face of it, a blowout. Revenue rose 23% to $305 million, organic growth was nearly 10%, adjusted EBITDA grew 38% to $80 million for a record 26% margin, and adjusted EPS rose 21% to $1.05. Bookings grew 29%, book-to-bill was 1.08, and backlog ended at $543 million with core backlog up 14%. The Medical Solutions segment grew 30% reported and about 3% organic, while advanced surgical technologies grew 66% reported and 12% organic. Management called it the strongest strategic and financial position in more than a decade. The stock disagreed. NOVT is down 16.3% over the last 90 trading days and 26.7% from its August 17 peak. Some of that is sector beta: the global tape has been punishing the AI infrastructure complex, with AI data centers among the 30-day decliners. But the company-specific reason is in the fourth-quarter guide. Revenue is guided to $306 million-$312 million, organic growth of 5%-7%, adjusted EBITDA of $76 million-$79 million, and adjusted EPS of $0.91-$0.96. The full-year adjusted gross margin is now expected at about 46.5%, and the Q4 margin is guided to roughly 46%—not the 48% management had been signaling.What actually broke: Stockport and the cost of consolidation
The culprit is a single U.K. factory. At Stockport, a major end user found an issue in testing, and Novanta stopped shipping while it corrects the problem. The program is not lost; shipments are expected to restart in the first quarter. But the timing collides with the company’s multiyear manufacturing consolidation, which is already carrying redundant factory costs as two factories move into the site.That is the tension. Management frames this as a temporary headwind, and the CEO was explicit: “The program is not in jeopardy. The customer wants this product.” — Matthijs Glastra, Chair and Chief Executive Officer · 2026-11-10 But the “temporary” label has a history. On the August call, the CFO had already promised the back half would run near 48% and that 2027 would add another 100 basis points: “We delivered a 47% gross margin in the second quarter. We're looking at something closer to 48% in the back half of the year. And I would expect that to maintain into 2027. So we're looking at another 100 basis points of improvement in 2027.” — Robert Buckley, Chief Financial Officer · 2026-08-06 Now the full-year number is 46.5%, and the fourth quarter is 46%. The 2027 target still exists—management reiterated at least 100 basis points of gross-margin expansion—but it now depends on a Q1 restart and a Q2 bounce. And redundant manufacturing costs are not a one-off; they have been a recurring feature of the site-consolidation story. A year ago, the CFO described the regional manufacturing program as worth “roughly about 100 basis points of incremental margin expansion” even after duplication. “it's roughly about 100 basis points of incremental margin expansion despite the fact that a traditional regional manufacturing initiative would result in duplication of manufacturing and duplication of cost structure.” — Robert Buckley, Chief Financial Officer · 2025-11-04 The market has heard this before.Yes, let me just add to that you have somewhat of a perfect storm happening there. You do have redundant costs because we are moving two factories into that location... There's roughly a 200 basis point impact as a consequence of this, so we're reporting something closer to 46% in the fourth quarter. It should be 48%.